Oncology Medical News about squamous cell carcinoma of the larynx and pharynx;platin-based exclusive chemotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx
Cancer, 06/30/09

Holsinger FC et al. - In a study to determine the long-term outcomes of pts with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy, it was reported that for selected pts, EC may provide long-term, durable disease control. For pts who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of pts.

Methods

142 who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 yrs or until death.
35 pts had >10 yrs of follow-up.

Results

Survival rates at 1 yr and 5 yrs were 95.8% and 61.2%, respectively.
The main causes of death were metachronous second primary tumors (n=27) and intercurrent disease (n=21).
Death related to EC was not encountered, and only 2 pts (1.4%) had grade 4 toxicity.
In multivariate analysis, primary tumor arising outside the glottic larynx and a Charlson comorbidity index >1 were associated with a statistically significant reduction in survival.
1-yr and 5-yr Kaplan-Meier local control estimates were 76.1% and 50.7%, respectively.
Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in pts who had glottic cancer to 88.7% in pts who had tumor originating from other sites.
Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for successful modulation of local therapy in 54.9% of pts.

<< Previous
Age-appropriate use of human papillomavirus vaccines in the US

Next >>
CD83 polymorphisms and cervical cancer risk